Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6572ff5df928fd17340eb2a8cb6d8502 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate |
2018-01-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_98e29b8fbd1905737c94489f02aaf529 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62bcd9fdd4cfde75dbc43bbce0f84227 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be9d6c08dc0056a075bd7ee21b18b404 |
publicationDate |
2018-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CO-2018000953-A2 |
titleOfInvention |
Association between 3 - [(3 - {[4- (4-morpholinylmethyl) -1h-pyrrol-2-yl] methylene} -2-oxo-2,3-dihydro-1h-indole-5-yl) methyl] -1,3-thiazolidine-2,4-dione and an inhibitor of egfr tyr kinase |
abstract |
The present invention relates to an association between 3 - [(3 - {[4- (4-morpholinylmethyl) -1H-pyrrol-2-yl] methylene} -2-oxo-2,3-dihydro-1H-indole -5-yl) methyl] -1,3-thiazolidine-2,4-dione of formula (I): (SEE IMAGE ATTACHED TO APPLICATION) or one of its isomers Z or E and / or acid addition salts or to a pharmaceutically acceptable base; and an EGFR Tyr kinase inhibitor |
priorityDate |
2015-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |